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HistopathologyAbstract Objective: To determine the ultrasonographic and mammographic features of intraduc-
tal breast masses that may be associated with malignancy.
Patients and methods: We compared US and mammographic ﬁndings with the histopathology in
198 patients with 251 intraductal breast masses. The radiologist assessed US features of the mass,
its distance from the nipple, the pattern of duct ﬁlling by the mass, whether the mass involved the
branch ducts and the presence of abnormal axillary lymph nodes. The mammograms were assessed
for the presence of a mass, calciﬁcations, a mass with calciﬁcations and asymmetry.
Results: Histopathology revealed 46 malignant masses (18.3%) and 205 benign masses (81.7%).
Malignant masses were larger than benign masses, have greater distance from the nipple, commonly
ﬁlled the duct completely, extended outside the duct, and involved branch duct whereas benign
masses commonly ﬁlled the duct incompletely and none extended outside the duct or involved
branch duct. On mammography, clustered microcalciﬁcations were commonly associated with
malignant masses.
Conclusion: Intraductal masses completely ﬁlled duct, extended outside the duct or involved
branch ducts, its distance from the nipple is >15 mm or associated with abnormal axillary lymph
nodes on US or microcalciﬁcations on mammography, and all these ﬁndings may be associated with
malignancy.
 2015 The Authors. The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Breasts are made up of lobules (milk-producing glands) and
ducts (tubes that carrymilk to the nipple), which are surrounded
by glandular, ﬁbrous and fatty tissue. Intraductal breast masses
are either solitary or multiple intraluminal lesions that develop
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usually close to the nipple, but can sometimes be found else-
where in the breast. The patient may feel a small painless lump
or notice a discharge of clear or bloodstained ﬂuid from the nip-
ple (1,2). A mass within a dilated duct can be either malignant
such as ductal carcinoma in situ (DCIS) and invasive ductal car-
cinoma (IDC)) or benign such as debris, papilloma, ﬁbroade-
noma and atypical ductal hyperplasia (3).
Recent advances in breast US technology using high-
resolution transducers (10–13 MHz), have enabled US to
clearly visualize the ductal system and have allowed the detec-
tion of intraductal masses (3). US is more speciﬁc than galac-
tography, mammography and MRI in the assessment of
intraductal masses and may be considered as the modality of
choice (4–7). US can reveal a solid oval, round, or microlobu-
lated mass in a ﬂuid-ﬁlled duct. On mammography, a round,
well-circumscribed mass, which may contain calciﬁcations,
can be seen in the subareolar region. Often US, and mammog-
raphy are non-revealing. Galactography can depict an intra-
ductal or intraluminal ﬁlling defect (8).
A standardized lexicon for breast US was developed in 2003
by the American College of Radiology in light of the increas-
ing use of US in clinical practice. Like its mammographic
counterpart, the sonographic Breast Imaging Reporting and
Data System (BI-RADS) lexicon was intended to provide a
uniﬁed language for sonographic reporting and research and
to avoid ambiguity in the communication and teaching of
sonographic interpretation (3). According to the BI-RADS
system, intraductal masses are one of the ‘‘special cases’’ and
it is still not clear whether all intraductal masses detected by
breast US should be classiﬁed into BI-RADS category 4A
because there are no deﬁnite clinical and radiologic predictors
for malignancy (3).
To our knowledge, only one study has assessed the ﬁnal
outcomes of intraductal masses detected by breast US aiming
to deﬁne the clinical and radiologic predictors for malignancy
(3). However, most of intraductal masses detected in this study
were conﬁrmed by histopathologic examination using core
needle biopsy or vacuum-assisted biopsy and surgical diagno-
sis was made for small number of cases. Thus, there are possi-
bilities of false-negative results from these biopsy procedures
that result in underestimation of the malignancy rate and
affect the ﬁnal outcome (3).
Therefore, it would be useful to identify the factors
involved in predicting the presence of malignancy within intra-
ductal breast masses based on surgical pathologic diagnosis to
obtain more accurate results.
For this reason, we compared the sonographic and mam-
mographic features of intraductal breast masses with the
histopathological results obtained after surgery aiming to
determine which sonographic and mammographic variables
of these masses may be associated with malignancy.
2. Patients and methods
2.1. Patients
At our institution, breast US is a basic examination for all
patients referred for any radiological breast study. Breast US
can be performed as a requested study or as a complementary
examination for mammography or MRI. Out of the 9534patients who underwent 19,513 US breast examinations
between March 2010 and September 2014, breast US suggested
the presence of intraductal masses in 215 patients. Of these, sur-
gery was performed for 200 patients followed by histopatholog-
ical examination which proved the presence of intraductal
masses in 198 patients. Among the remaining 15 patients, 9
patients refused surgery and 6 patients underwent US without
mammography due to lactation. The inclusion criterion for this
study was histopathologically-proven intraductal masses in
patients who underwent both breastUS andmammography fol-
lowed by surgical excisional biopsy. Therefore, this study
included 198 patients and the remaining 17 patients were
excluded (two patients with negative histopathology after sur-
gery, 6 patients who underwent breast US only and 9 patients
who refused surgery). Among the 198 patients, 19 patients had
two lesions and ﬁve patients had three lesions. Thus, 251 intra-
ductal masses from 198 patients were retrospectively included in
this study. All patients were females and their ages ranged from
24 to 73 years (median age, 38 years).
3. Methods
All patients underwent a clinical breast examination before
breast US and mammography. The mammograms were
performed using a LABDA/GMI (General Medical Italy)
mammography system (LABDA/GMI, Italy). Standard
craniocaudal and mediolateral oblique views were routinely
obtained, and additional mammographic views were used as
needed.
Breast US was performed by an experienced radiologist
using a scanner (Mindray DC-7) and a scanner (Medison
SONOACE R7), both scanners with 5–12 MHz linear-array
transducers. US of both breasts was performed ﬁrst by scan-
ning each breast in the transverse and sagittal orientations,
inner aspect of the breast in a supine position, and outer aspect
in supine oblique position with the patient’s arm raised above
the head. The radiologist assessed the presence of breast
masses, the lactiferous ducts and periductal area, and the axil-
lary tail followed by scanning the axilla. In cases of palpable
abnormality, targeted scanning at the area of concern was per-
formed: the radiologist palpated the lesion before and during
scanning of the lesion.
Meticulous scanning of the periareolar region was per-
formed after optimization of the sonographic parameters as
follows: frequency (FR) = 12, frame rate (FR) = 9 Hz,
Dynamic range (DR) = 60–75 with lower values for dense
breast tissue and higher values for normal breast tissue, Gain
(Gn) = 80–95, Focus position = 2. We used generous amount
of gel at the areolar region together with light compression of
the probe and scanning is done laying the probe in parallel
with the long and short axes of the lactiferous duct. In patients
with retracted or deformed nipple obscuring the retro-areolar
region in supine position, examination was better performed
in supine oblique position for better delineation of the ducts.
The assessment of US and mammographic ﬁndings was
done separately by the same radiologist who was blinded
about the ﬁnal diagnosis obtained after histopathological
examination.
The mammograms were assessed for the presence of calciﬁ-
cations, mass (localized abnormal density), a mass with calciﬁ-
cations and asymmetry (9).
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number, size, shape, margin, echogenicity and their distance
from the nipple. The degree of ﬁlling of the lactiferous duct
by the mass and whether the mass involved the branch duct
was also identiﬁed (3,10). In addition, the axillary lymph nodes
were assessed for their shape, length, width, echogenicity, cor-
tical thickness and the shape of the central hilum. An abnor-
mal lymph gland was deﬁned as a lymph node with an
eccentric or irregular cortical thickening (usually > 3 mm),
round shape (short-to-long diameter ratio > 0.5), change in
internal echogenicity (hyperechoic, cystic change, or calciﬁca-
tion), or abnormal central echogenic hilum (absent or com-
pressed) (11,12).
Surgery was done for all intraductal breast masses.
Palpation-guided surgical excision and a microdochectomy
(removal of the affected duct or ducts) were performed for
lesions that were deﬁnitely palpable on clinical examination
by the surgeon (n= 64). In cases of non-palpable lesions
(n= 187), surgical excision and a microdochectomy were per-
formed after US-guided localization of these lesions in the
operation room using a guide wire (Vivant Medical, Inc.,
Palo Alto, CA) which was placed to one side of the lesion as
illustrated in our previous study (13). In patients with suspi-
cious axillary lymph nodes on US (n= 12), clearance of the
axilla was performed. The excised specimens were sent for
pathologic examination and post-surgical management was
done according to the results of histopathological examination
as mentioned in the literature (14,15). In cases where benign
histology was noted, follow-up US was recommended for
24 months. In cases with multiple intraductal papillomas
(n= 5) or atypical ductal hyperplasia (n= 14), close follow-
up with screening mammography was recommended for
24 months after surgical excision because these women have
a 1.5- to 2-time relative risk of developing invasive breast car-
cinoma in their lifetimes. In cases with ductal carcinoma in situ
(n= 31), radiotherapy was recommended after surgical exci-
sion. In cases with invasive breast carcinoma (n= 15), lumpec-
tomy (n= 12) or mastectomy (n= 3) was done followed by a
combination of either radiotherapy, chemotherapy or hor-
monal therapy. Mastectomy was performed as a second oper-
ation for 8 patients with invasive ductal carcinoma.
The US and mammographic ﬁndings were correlated with
the subsequent histopathological results obtained after surgery
to determine the US and mammographic features of
malignancy.
Chi-square test was used for statistical data analysis.
4. Results
Histopathological examinations of the 251 intraductal masses
revealed 46 malignant masses (18.3%) and 205 benign masses
(81.7%). Malignant masses were 31 ductal carcinomas in situ
(Fig. 4) and 15 invasive ductal carcinomas (Figs. 5 and 6)
and benign masses included 162 papillomas (Figs. 1–3), 13
duct ectasias, 4 ﬁbroadenomas and 14 atypical ductal
hyperplasias.
Regarding mammographic ﬁndings of intraductal breast
masses, most of intraductal breast masses showed negative
mammographic ﬁndings (63.4 of benign masses and 37% of
malignant masses) (Fig. 1). The presence of clustered microcal-
ciﬁcations showed signiﬁcant differences between benign andmalignant intraductal masses (17.4% of malignant masses
showed clustered microcalciﬁcations vs 1.9% for benign
masses, p< 0.001). Other mammographic ﬁndings, such as
asymmetry, mass, and mass with microcalciﬁcations (Fig. 6)
were not signiﬁcantly different between benign and malignant
intraductal masses. The mammographic ﬁndings between
benign and malignant intraductal masses are summarized in
Table 1.
Regarding US ﬁndings of intraductal breast masses, the US
features of the mass such as the size (mean diameter), the mar-
gins of the mass and its distance from the nipple showed signif-
icant differences between benign and malignant masses.
Malignant intraductal masses were larger than benign masses
(the mean size was 18 mm; range, 4–38 mm vs 8 mm; range,
2–20 mm for benign masses), and their margins were com-
monly irregular (47.8% vs 3.4% for benign masses) and have
greater distance from the nipple than benign masses (average
distance was 22 mm; range, 5–53 mm vs 9 mm; range, 3–
15 mm for benign masses). Regarding the number of intraduc-
tal masses, multiple lesions were more commonly benign (23%
of benign masses were multiple vs 8.7% for malignant masses)
(Fig. 3) but the difference was not statistically signiﬁcant.
Other features such as the shape and mass echogenicity
showed no signiﬁcant differences between benign and malig-
nant masses.
The pattern of duct ﬁlling by the mass, involvement of
branch duct by the mass and the presence of abnormal axillary
lymph nodes showed signiﬁcant differences between benign
and malignant masses. For malignant intraductal masses,
73.9% of masses completely ﬁlled the duct, 17.4% completely
ﬁlled the duct and extended outside the duct wall (Fig. 5) and
8.7% incompletely ﬁlled the duct (Fig. 4). In addition, 34.8%
of malignant masses involved branch ducts (Fig. 6). By con-
trast for benign intraductal masses, 93.7% of masses incom-
pletely ﬁlled the duct (Figs. 1–3) and 6.3% completely ﬁlled
the duct. No benign intraductal mass extended outside the
duct or involved branch duct.
Twelve malignant intraductal masses (26%) were associ-
ated with abnormal axillary lymph nodes (Fig. 6) whereas
none of the benign masses had abnormal axillary lymph nodes.
Eight masses had abnormal axillary lymph nodes that were
completely hypoechoic with absent central echogenic hilum
and 4 masses had lymph nodes that showed irregular cortical
thickening more than 3 mm. No lymph nodes had internal cal-
ciﬁcations or cystic changes. The US ﬁndings between benign
and malignant intraductal masses are summarized in Table 2.
5. Discussion
Although the malignant intraductal breast masses comprise a
very narrow sample size, the ability to identify patients with
a high possibility of intraductal malignant breast masses might
allow to make more accurate surgical plans and to reduce the
potential patient risk and overall medical costs.
The results of our study showed higher malignancy rate
(18.3%) compared to those reported by previous authors
(8%) (3). This may be explained by the difference in the gold
standard. The previously reported lower malignancy rate was
based mainly on the histopathologic results obtained after
US-guided core biopsy or vacuum – assisted biopsy for most
intraductal masses (133 out of 163 masses). This may lead to
A B
Fig. 1 Benign intraductal mass incompletely ﬁlls the duct in 52-year-old woman. US image (A) shows small (3 mm) solid isoechoic mass
that incompletely ﬁlls a ﬂuid-ﬁlled duct in the right breast (arrow). Mammographic image craniocaudal view (B) shows negative ﬁnding.
Histopathology result revealed duct papilloma.
A B
Fig. 2 Benign intraductal mass incompletely ﬁlls the duct in 36-year-old woman. US image (A) shows 5 · 3 mm solid isoechoic mass (M)
that incompletely ﬁlls a ﬂuid-ﬁlled duct in the right breast. Mammographic image craniocaudal view (B) shows small subareolar mass with
smooth margins (arrows). Histopathology result revealed duct papilloma.
A B
Fig. 3 Multiple benign intraductal masses incompletely ﬁll the duct in 43-year-old woman. US image (A) shows three small solid
isoechoic masses ranging from 2 to 4 mm that incompletely ﬁll a ﬂuid-ﬁlled duct in the left breast (arrows). Mammographic images in
craniocaudal view (B) show heterogeneously dense breast parenchyma with no localized masses. Histopathology result revealed multiple
duct papillomas.
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from biopsy can result in the histologic underestimation of
lesions containing atypical ductal hyperplasia or ductal carci-
noma in situ, as well as invasive carcinomas (14). On the other
hand, the malignancy rate in our study was based on
histopathologic results obtained after surgery for all intraduc-
tal masses detected on breast US giving accurate detection and
conﬁrmation of the nature of these masses.
A previous study by Kim et al. (3), mentioned that no
mammographic ﬁndings can differentiate malignant frombenign intraductal breast masses. In our study, we found that
most of malignant and benign intraductal breast masses
showed negative mammographic ﬁndings (61.8% of benign
masses and 37% of malignant masses). The possible explana-
tion for inability of mammography to detect intraductal
masses may be the small size of these masses and their location
as most of these lesions arise at the retroareolar region which is
usually dense making difﬁcult identiﬁcation of these masses.
However, the presence of microcalciﬁcations was commonly
associated with malignant intraductal masses and the
Table 1 Comparison of mammographic ﬁndings between
benign and malignant intraductal masses.
Mammographic
ﬁnding
Type of masses P-value
Benign
N= 205
Malignant
N= 46
Negative 130 (63.4%) 17 (37%) 0.503
Asymmetry 22 (10.7%) 4 (8.7%) 0.408
Microcalciﬁcation 4 (1.9%) 8 (17.4%) <0.001
Mass 46 (22.4%) 13 (28.2%) 0.113
Mass with
microcalciﬁcation
3 (1.5%) 4 (8.7%) 0.603
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masses vs 1.9% for benign masses).
In our study, most of the US features of intraductal masses
showed signiﬁcant differences between benign and malignant
lesions such as the size, the margins of the mass and its
distance from the nipple. Malignant intraductal masses were
larger than benign masses (their average diameter was
18 mm vs 8 mm for benign masses), and their margins were
commonly irregular and have greater distance from the nipple
(their average distance from the nipple was 22 mm vs 9 mm for
benign masses). However, regarding the number of intraductal
masses, multiple lesions were more commonly benign but the
difference was not statistically signiﬁcant. Similar results have
been mentioned by previous authors (3). However, in discor-
dance with our study, they found that the mean distance from
the nipple of the malignant intraductal masses was greater
than of benign intraductal masses but the difference was not
statistically signiﬁcant (average distance of malignant masses
from the nipple was 12.7 mm vs 8.5 mm for benign masses).
In agreement with our results, Osuch (14) mentioned that
90% of benign intraductal masses arise within 10 mm of the
nipple. Considering our results and those mentioned in the pre-
vious studies, it may be reasonable to consider intraductal
masses that are greater than 15 mm in diameter and those that
have distance from the nipple greater than 15 mm are probably
malignant.
The pattern of ﬁlling of the lactiferous ducts by the mass
and involvement of the branch ducts by the mass wereBA
Fig. 4 Malignant intraductal mass incompletely ﬁlls the duct in 50-ye
incompletely ﬁlls a ﬂuid-ﬁlled duct in the right breast. The mass
Mammographic image in craniocaudal view (B) shows scattered ﬁbrog
revealed ductal carcinoma in situ.characteristic US features that could differentiate malignant
from benign intraductal masses in our study. We found that
73.9% of malignant intraductal masses ﬁlled the duct com-
pletely, 17.4% ﬁlled the duct completely and extended outside
the duct wall and 8.7% incompletely ﬁlled the duct. In addi-
tion, involvement of the branch duct was seen in 34.8% of
malignant intraductal masses. On the other hand, we found
that 93.7% of benign intraductal masses incompletely ﬁlled
the duct and only 6.3% ﬁlled the duct completely. No benign
intraductal mass extended outside the duct or involved branch
duct. Therefore, the majority of intraductal masses that com-
pletely ﬁlled the duct were malignant whereas the majority of
intraductal masses that incompletely ﬁlled the duct were
benign. In addition, all intraductal masses that completely
ﬁlled the duct and extended outside the duct or involved
branch ducts were malignant.
In agreement with our results, previous authors have found
that 69.3% of malignant intraductal masses ﬁlled the duct
completely and 30.7% ﬁlled the duct completely and extended
outside the duct wall (3). However, in discordance with our
results, they have found that 73% of benign intraductal masses
completely ﬁlled the duct, 24.5% incompletely ﬁlled the duct
and 2.5% completely ﬁlled the duct and extended outside.
Therefore, intraductal masses that completely ﬁlled the duct
were either benign or malignant whereas all intraductal masses
that incompletely ﬁlled the duct were benign. However, these
results are limited because the number of intraductal masses
that incompletely ﬁlled the duct was relatively small (37 of
150 benign masses).
Although our study was conﬁned to intraductal breast
masses with the rare possibility of axillary lymph node
metastasis as most intraductal breast masses are benign, we
evaluated the axillae in all patients to assess the presence of
abnormal axillary lymph node as an additional sonographic
ﬁnding that may be associated with malignant intraductal
masses mainly in patients with invasive breast cancers which
are populations that already have a high likelihood of axillary
lymph node metastases (9). Based on the previously published
diagnostic criteria to deﬁne suspicious lymph nodes on US
(11,12), we identiﬁed abnormal axillary lymph nodes in 26%
of malignant intraductal masses, all had invasive breast can-
cers on histopathological examination. None of the 205ar-old woman. US image (A) shows 7 · 5 mm solid mass (M) that
shows non-homogenous echogenicity with irregular margins.
landular tissue with localized mass (arrow). Histopathology result
. 
BA 
Fig. 5 Malignant intraductal mass completely ﬁlls the duct and extends outside the duct wall in 55-year-old woman. US image (A) shows
15 · 10 mm solid hyperechoic mass (M) that completely ﬁlls the duct and extends outside the duct wall in the left breast. Mammographic
image craniocaudal view (B) shows retroareolar localized mass having irregular margins (arrow). Histopathology result revealed invasive
ductal carcinoma.
 
B C A 
Fig. 6 Malignant intraductal mass completely ﬁlls the duct and involves branch duct in 58-year-old woman. US image (A) shows
32 · 27 mm solid mass that completely ﬁlls the duct (long arrows) and extending to a branch duct (short arrow) in the left breast. The mass
appears hypoechoic with irregular margins. US image for axilla (B) shows an enlarged axillary lymph node (N) measuring 25 · 13 mm and
appears hypoechoic with loss of the central hilum (long arrow), suspicious of malignancy. Magniﬁed mammographic image mediolateral
(oblique) view (C) shows localized mass having irregular margins and cluster of microcalciﬁcations (long arrows). Note retraction of the
nipple (short arrow). Histopathology result revealed invasive ductal carcinoma with metastatic axillary lymph nodes.
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lymph node.
Management of intraductal breast masses detected on US is
controversial. Some authors support performing core biopsy
for suspicious masses and follow-up US for benign masses
(16) whereas other authors support performing core biopsy
for all intraductal masses detected on US (3). In cases where
benign histology is noted on core biopsy, a conservative
approach and follow-up is indicated. Surgery is indicated for
lesions that conﬁrmed histopathologically to be malignant by
core biopsy and for lesions with atypical pathological results
(3,16). However, core biopsy can result in underestimation of
malignant lesions, a problem that has an impact on proper
management. For a lesion diagnosed as ADH on needle biopsy
and DCIS at surgery, underestimation is important because it
could lead to a positive margin following surgical resection.
Lesions diagnosed as DCIS on needle biopsy and unsuspected
invasive carcinoma at surgery result in delayed lymph node
biopsies. Thus, patients may have to undergo two separate sur-
gical procedures: one procedure for excision of the lesion and
an additional procedure for axillary lymph node evaluation
(17).
Therefore, to avoid underestimation of malignant lesions in
our study, surgery was done for all intraductal breast masses.For masses that were deﬁnitely palpable on clinical examina-
tion by the surgeon, palpation-guided surgical excision and a
microdochectomy were performed. In cases of non-palpable
masses, surgical excision and a microdochectomy were
performed after US-guided localization of these masses in
the operation room after placement of a guide wire to one side
of the mass as we have a good experience in such interven-
tional procedure as mentioned in our previously published
study (13). Post-surgical management was done according to
the results of histopathological examination as mentioned in
the literature (14,15).
Our suggested protocol for the management of intraductal
breast masses is to perform breast US for all patients attending
for any radiologic breast study to avoid missing small intra-
ductal masses that can be easily undetected on mammography.
The proper management for intraductal breast masses that
have US or mammographic ﬁndings suspicious for malignancy
without suspicious axillary lymph nodes on US may be surgi-
cal excision and pathological examination of the mass whereas
those masses that associated with suspicious axillary lymph
nodes should undergo core biopsy to be certain of the diagno-
sis as these patients will undergo mastectomy and clearance of
the axilla. Core biopsy is better to be done also for masses hav-
ing benign sonographic and mammographic features. All
Table 2 Comparison of US ﬁndings between benign and malignant intraductal masses.
US ﬁnding Type of masses P-value
Benign N= 205 Malignant N= 46
US features of the mass:
Mean diameter (mm) 8 18 <0.001
Number:
Single 158 (77%) 42 (91.3%) 0.437
Multiple 47 (23%) 4 (8.7%)
Shape:
Round 28 (13.7%) 16 (34.8%) 0.527
Oval 177 (86.3%) 30 (65.2%)
Margin:
Regular 198 (96.6%) 24 (52.2%) <0.001
Irregular 7 (3.4%) 22 (47.8%)
Echogenicity:
Isoechoic (to the duct wall) 112 (54.6%) 22 (47.8%) 0.623
Hyperechoic 16 (7.8%) 2 (4.4%)
Hypoechoic 68 (33.2) 16 (34.8%)
Mixed 9 (4.4%) 6 (13%)
Average distance from the nipple (mm) 9 22 <0.001
Duct ﬁlling by the mass:
Incomplete duct ﬁlling 192 (93.7%) 4 (8.7%) <0.001
Complete duct ﬁlling 13 (6.3%) 34 (73.9%)
Complete ﬁlling with extension outside the duct 0 (0%) 8 (17.4%)
Involvement of branch duct by the mass:
Yes 0 (0%) 16 (34.8%) <0.001
No 205 (100%) 30 (65.2%)
Abnormal lymph node in the axilla 0 (0%) 12 (26%) <0.001
Intraductal breast masses 1277specimens must be sent for pathological examination. In cases
with benign histopathology, follow-up US is advised for
24 months; however, in cases with atypical ductal hyperplasia,
follow-up may include mammography in addition to US.
Cases with ductal carcinoma in situ should perform radiother-
apy after surgical excision and cases with invasive breast carci-
noma, should be followed by a combination of either
radiotherapy, chemotherapy or hormonal therapy after
mastectomy.
In conclusion, although most intraductal breast masses are
benign, the presence of intraductal breast masses completely
ﬁlled the duct, extended outside the duct or involved branch
ducts as well as intraductal masses that associated with abnor-
mal axillary lymph nodes, masses larger than 15 mm or their
distance from the nipple is greater than 15 mm, and all these
US ﬁndings may be associated with malignancy. Intraductal
breast masses that show clustered microcalciﬁcations on mam-
mography are probably malignant.
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